Literature DB >> 30328027

Relationships of high cardiac output with ventricular morphology, myocardial energetics, and energy costs in hemodialysis patients with preserved ejection fraction.

Tomonari Harada1, Masaru Obokata2, Koji Kurosawa3, Hidemi Sorimachi1, Kuniko Yoshida1, Hideki Ishida4, Kyoko Ito4,5, Tetsuya Ogawa4,6, Yoshitaka Ando4, Masahiko Kurabayashi1, Kazuaki Negishi1,7,8.   

Abstract

Hemodialysis patients have conditions that increase cardiac output (CO), including arteriovenous fistula, fluid retention, vasodilator use, and anemia. We sought to determine the relationships between these factors and CO and to evaluate the effects of the high-output states on ventricular morphology, function, and myocardial energetics in hemodialysis patients, using noninvasive load-insensitive indices. Cardiovascular function was assessed in hemodialysis patients with high output [ejection fraction ≥ 50%, cardiac index (CI) > 3.5 L/min/m2, n = 30], those with normal output (CI < 3.0 L/min/m2, n = 161), and control subjects without hemodialysis (n = 155). As compared to control subjects and hemodialysis patients with normal CI, patients with elevated CI were anemic and displayed decreased systemic vascular resistance index (SVRI), excessive left ventricular (LV) contractility, larger LV volume, and tachycardia. Lower hemoglobin levels were correlated with decreased SVRI, excessive LV contractility, and higher heart rate, while estimated plasma volume and interdialytic weight gain were associated with larger LV volume, thus increasing CO. High output patients displayed markedly increased pressure-volume area (PVA) and PVA/stroke volume ratio, which were correlated directly with CO. The use of combination vasodilator therapy (angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker and calcium channel blocker) was not associated with high-output states. In conclusion, anemia and fluid retention are correlated with increased CO in hemodialysis patients. The high-output state is also associated with excessive myocardial work and energy cost.

Entities:  

Keywords:  Anemia; Cardiac output; Fluid retention; Hemodialysis; Myocardial energetics

Mesh:

Substances:

Year:  2018        PMID: 30328027     DOI: 10.1007/s10554-018-1472-4

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  34 in total

1.  Effect of closure of the arteriovenous fistula on left ventricular dimensions in renal transplant patients.

Authors:  E C van Duijnhoven ; E C Cheriex; J H Tordoir; J P Kooman; J P van Hooff
Journal:  Nephrol Dial Transplant       Date:  2001-02       Impact factor: 5.992

2.  Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF.

Authors:  Yoshio Iwashima; Takeshi Horio; Yoichi Takami; Takashi Inenaga; Toshio Nishikimi; Shuichi Takishita; Yuhei Kawano
Journal:  Am J Kidney Dis       Date:  2002-11       Impact factor: 8.860

3.  Cardiac effects of persistent hemodialysis arteriovenous access in recipients of renal allograft.

Authors:  J J De Lima; M L Vieira; L J Molnar; C J Medeiros; L E Ianhez; E M Krieger
Journal:  Cardiology       Date:  1999       Impact factor: 1.869

4.  Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis.

Authors:  Kamyar Kalantar-Zadeh; Deborah L Regidor; Csaba P Kovesdy; David Van Wyck; Suphamai Bunnapradist; Tamara B Horwich; Gregg C Fonarow
Journal:  Circulation       Date:  2009-01-26       Impact factor: 29.690

5.  Blood viscosity and cardiac output in acute experimental anemia.

Authors:  N O Fowler; J C Holmes
Journal:  J Appl Physiol       Date:  1975-09       Impact factor: 3.531

6.  Long-term effects of arteriovenous fistula closure on echocardiographic functional and structural findings in hemodialysis patients: a prospective study.

Authors:  Ezio Movilli; Battista Fabio Viola; Giuliano Brunori; Paola Gaggia; Corrado Camerini; Roberto Zubani; Nicola Berlinghieri; Giovanni Cancarini
Journal:  Am J Kidney Dis       Date:  2010-01-20       Impact factor: 8.860

7.  Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations.

Authors:  Miho Kawaguchi; Ilan Hay; Barry Fetics; David A Kass
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

8.  Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug; Carolyn S P Lam; Véronique L Roger; Richard J Rodeheffer; Margaret M Redfield
Journal:  J Am Coll Cardiol       Date:  2009-07-28       Impact factor: 24.094

9.  The impact of arteriovenous fistula formation on central hemodynamic pressures in chronic renal failure patients: a prospective study.

Authors:  M Tessa Savage; Charles J Ferro; Antonio Sassano; Charles R V Tomson
Journal:  Am J Kidney Dis       Date:  2002-10       Impact factor: 8.860

Review 10.  End-stage renal disease in the United States: an update from the United States Renal Data System.

Authors:  Robert N Foley; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121

View more
  2 in total

1.  Left ventricular outflow tract velocity time integral in hospitalized heart failure with preserved ejection fraction.

Authors:  Kazunori Omote; Toshiyuki Nagai; Hiroyuki Iwano; Shingo Tsujinaga; Kiwamu Kamiya; Tadao Aikawa; Takao Konishi; Takuma Sato; Yoshiya Kato; Hirokazu Komoriyama; Yuta Kobayashi; Kazuhiro Yamamoto; Tsutomu Yoshikawa; Yoshihiko Saito; Toshihisa Anzai
Journal:  ESC Heart Fail       Date:  2019-12-18

2.  Increased Excess Pressure After Creation of an Arteriovenous Fistula in End-Stage Renal Disease.

Authors:  Mathilde Paré; Rémi Goupil; Catherine Fortier; Fabrice Mac-Way; François Madore; Bernhard Hametner; Siegfried Wassertheurer; Martin G Schultz; James E Sharman; Mohsen Agharazii
Journal:  Am J Hypertens       Date:  2022-02-01       Impact factor: 2.689

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.